Showing 651-660 of 8844 results for "".
New Analysis of Benzene Contamination in BPO Products
https://practicaldermatology.com/series/dermwire-tv/new-analysis-benzene-contamination-bpo-products/29074/In this week's DermwireTV, new data continues to raise concerns about benzene contamination in BPO products; the FDA expands the approved dosage for Ameluz for actinic keratosis (AK); and in our PA Perspectives segment, Andrew Mastro discusses how to approach a contract negotiation.Journal Club: Updates in Topical Treatments for AD
https://practicaldermatology.com/series/practical-dermatology-journal-club-atopic-dermatitis/journal-club-updates-topical-treatments-ad/29744/Editorial Board member and dermatologist Dr. Peter Lio talks with Dr. Ted Lain, a dermatologist at Sanova Dermatology, about the latest research and developments in topical treatments for AD. The discussion covers a range of therapies highlighted in an article from the Dermatologic Clinics article "ISDPA: Dr. Lio on Alternative and Innovative Approaches
https://practicaldermatology.com/conferences/isdpa-midwest-derm-2024/isdpa-dr-lio-alternative-and-innovative-approaches/27066/Practical Dermatology Editorial Board member Peter Lio, MD, discusses the presentation that he and Tracee Blackburn, PA-C, gave about alternative and innovative approaches in dermatology, as well as the importance of educational engagement between physician assistants and dermatologists, at the IlliNoah Worcester 2024: Dr. Bhatia on Actinic Keratosis
https://practicaldermatology.com/conferences/noah-worcester-2024/noah-worcester-2024-dr-bhatia-actinic-keratosis/24585/Neal Bhatia, MD, FAAD, summarizes his lecture on actinic keratosis and photodynamic therapy at the 2024 Noah Worcester Dermatological Society meeting.DermWireTV: Birch Triterpenes Gel Gets FDA Approval for EB, VTE Risk is Lower in Patients with AD, and Are Topical Steroids Affecting Bone Health?
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-birch-triterpenes-t-gel-gets-fda-approval-for-eb-vte-risk-is-lower-in-patients-with-ad-and-are-topical-steroids-affecting-bone-health/20233/A birch bark extract topical from Chiesi Global Rare Diseases represents the latest in treatment approvals for epidermolysis bullosa. Patients with atopic dermatitis may have a decreased risk for developing venous thromboembolism. Commonly prescribed topical steroids may raise some patients' risk foNew Drugs Helping AD Catch Up to Psoriasis
https://practicaldermatology.com/series/updates-atopic-dermatitis/new-drugs-helping-ad-catch-psoriasis/28650/Dr. H.L. Greenberg, a board-certified dermatologist and founder of Las Vegas Dermatology®, talks with Practical Dermatology about some of the new drugs that are helping atopic dermatitis catch up to psoriasis in terms of available therapeutics.ASLMS New Beginnings Initiative
https://practicaldermatology.com/programs/practical-dermatology/aslms-new-beginnings-initiative/18188/In 2014, the American Society for Laser Medicine and Surgery started its New Beginnings initiative. Initially launched to benefit cancer survivors, ASLMS physicians volunteered to remove radiation tattoos pro bono. Recently, the ASLMS, under the leadership of its president Paul Friedman, MD, expandeRoflumilast Cream, 0.15%, for Atopic Dermatitis
https://practicaldermatology.com/issues/december-2024/Roflumilast-Cream-Atopic-Dermatitis/32840/Atopic dermatitis (AD) is a chronic, persistent inflammatory condition that significantly disrupts the quality of life of patients diagnosed with it. Moreover, AD presents challenges for clinicians when counseling patients on the management of their condition. Application frequency, treatment formulAdvancing Digital Medicine in Dermatology
https://practicaldermatology.com/programs/practical-dermatology/advancing-digital-medicine-in-dermatology/18187/The Digital Medicine Society (DiME) is a global nonprofit dedicated to advancing the ethical, effective, equitable, and safe use of digital medicine to redefine health care and improve lives. DiME recently released a new set of resources, available at www.dimesociety.org/access-resources/, to advancNew FDA Approval for AD
https://practicaldermatology.com/series/c-suite-chats/new-fda-approval-for-ad/29911/Phil Brown, MD, JD, Dermatologic Scientific Lead at Organon, talks about the importance of a new FDA-approved topical solution for treating atopic dermatitis.